Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：41

作者：

Doebele, R. ^{[1
]}

Ahn, M. ^{[2
]}

Siena, S. ^{[3
,4
]}

Drilon, A. ^{[5
]}

Krebs, M. ^{[6
]}

Lin, C. ^{[7
]}

De Braud, F. ^{[8
]}

John, T. ^{[9
]}

Tan, D. ^{[10
]}

Seto, T. ^{[11
]}

Dziadziuszko, R. ^{[12
]}

Arkenau, H. ^{[13
]}

Barlesi, F. ^{[14
]}

Rolfo, C. ^{[15
]}

Wolf, J. ^{[16
]}

Chow-Maneval, E. ^{[17
]}

Multani, P. ^{[17
]}

Cui, N. ^{[18
]}

Riehl, T. ^{[18
]}

Cho, B. C. ^{[9
]}

机构：

[1] Univ Colorado, Aurora, CO USA

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea

[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[4] Univ Milan, Milan, Italy

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA

[6] Univ Manchester, Manchester, Lancs, England

[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[9] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[10] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore

[11] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan

[12] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland

[13] Sarah Cannon Res Inst, London, England

[14] Aix Marseille Univ, AP HM, Marseille, France

[15] Antwerp Univ Hosp, Oncol Dept, Phase 1 Early Clin Trials Unit, Antwerp, Belgium

[16] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany

[17] Ignyta Inc, San Diego, CA USA

[18] Genentech Inc, San Francisco, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

NSCLC; entrectinib; ROS1 gene fusion;

D O I：

10.1016/j.jtho.2018.08.239

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA02.01

引用

页码：S321 / S322

页数：2

共 50 条

[21] Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Murakami, H.
Ohe, Y.
Hayashi, H.
Esaki, T.
Yamaguchi, T.
Fukuhara, T.
Daga, H.
Tanaka, H.
Kozuki, T.
Osborne, S.
Bordogna, W.
Goto, K.
ANNALS OF ONCOLOGY, 2022, 33 : S1594 - S1594
[22] Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
Lin, Jessica J.
Langenbucher, Adam
Gupta, Pranav
Yoda, Satoshi
Fetter, Isobel J.
Rooney, Marguerite
Do, Andrew
Kem, Marina
Chang, Kylie Prutisto
Oh, Audris Y.
Chin, Emily
Juric, Dejan
Corcoran, Ryan B.
Dagogo-Jack, Ibiayi
Gainor, Justin F.
Stone, James R.
Lennerz, Jochen K.
Lawrence, Michael S.
Hata, Aaron N.
Mino-Kenudson, Mari
Shaw, Alice T.
NPJ PRECISION ONCOLOGY, 2020, 4 (01)
[23] Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)
Liu, S. V.
De Braud, F.
Drilon, A.
Doebele, R. C.
Patel, M. R.
Cho, B. C.
Ahn, M. J.
Chiu, C. H.
Farago, A. F.
Goto, K.
Lee, J.
Ohe, Y.
Ou, S. H. I.
Cassier, P.
Tan, D. S. W.
Otterson, G. A.
Veronese, L.
Osborne, S.
Simmons, B.
Siena, S.
ANNALS OF ONCOLOGY, 2021, 32 (04) : 577 - 577
[24] Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition
Jessica J. Lin
Adam Langenbucher
Pranav Gupta
Satoshi Yoda
Isobel J. Fetter
Marguerite Rooney
Andrew Do
Marina Kem
Kylie Prutisto Chang
Audris Y. Oh
Emily Chin
Dejan Juric
Ryan B. Corcoran
Ibiayi Dagogo-Jack
Justin F. Gainor
James R. Stone
Jochen K. Lennerz
Michael S. Lawrence
Aaron N. Hata
Mari Mino-Kenudson
Alice T. Shaw
npj Precision Oncology, 4
[25] Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).
Cho, Byoung Chul
Drilon, Alexander E.
Doebele, Robert Charles
Kim, Dong-Wan
Lin, Jessica Jiyeong
Lee, Jeeyun
Ahn, Myung-Ju
Zhu, Viola Weijia
Ejadi, Samuel
Camidge, D. Ross
Liu, Yuwei Juliet
Stopatschinskaja, Shanna
Cui, Jingrong Jean
Hyman, David Michael
Ou, Sai-Hong Ignatius
Shaw, Alice Tsang
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[26] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
Zhou, Qing
Zhao, Jun
Chang, Jianhua
Wang, Huijie
Fan, Yun
Wang, Ke
Wu, Gang
Nian, Weiqi
Sun, Yuping
Sun, Meili
Wang, Xiangcai
Shi, Huaqiu
Zheng, Xiangqian
Yao, Sheng
Qin, Mengmeng
Shen, Zhenwei
Yang, Jason
Wu, Yi-Long
CANCER, 2023, 129 (20) : 3239 - 3251
[27] Entrectinib Approved for NTRK Fusion-Positive Solid Tumors and ROS1-Rearranged Non-Small Cell Lung Cancer
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 610 - 610
[28] Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Ou, S.
Cho, B. C.
Kim, D.
Drilon, A.
Lee, J.
Lin, J.
Zhu, V.
Ahn, M.
Camidge, D. R.
Stopatschinskaja, S. Shanna
Liu, J.
Cui, J.
Hyman, D.
Doebele, R.
Shaw, A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1047 - S1047
[29] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Drilon, Alexander
Siena, Salvatore
Dziadziuszko, Rafal
Barlesi, Fabrice
Krebs, Matthew G.
Shaw, Alice T.
de Braud, Filippo
Rolfo, Christian
Ahn, Myung-Ju
Wolf, Juergen
Seto, Takashi
Cho, Byoung Chul
Patel, Manish R.
Chiu, Chao-Hua
John, Thomas
Goto, Koichi
Karapetis, Christos S.
Arkenau, Hendrick-Tobias
Kim, Sang-We
Ohe, Yuichiro
Li, Yu-Chung
Chae, Young K.
Chung, Christine H.
Otterson, Gregory A.
Murakami, Haruyasu
Lin, Chia-Chi
Tan, Daniel S. W.
Prenen, Hans
Riehl, Todd
Chow-Maneval, Edna
Simmons, Brian
Cui, Na
Johnson, Ann
Eng, Susan
Wilson, Timothy R.
Doebele, Robert C.
LANCET ONCOLOGY, 2020, 21 (02): : 261 - 270
[30] A phase II study of SAF-189s in patients with advanced ROS1 fusion-positive non-small cell lung cancer
Yang, J.
Zhou, J.
Li, M.
Zhang, Z-Y.
Cheng, Y.
Chu, D. H.
Pan, H.
Wang, B.
Chen, G.
Wang, K.
Jiang, L.
Hu, Y.
Shi, J.
Hui, A-M.
Zhou, Y.
Wu, Z.
Sun, J.
Tan, Y.
Xiang, X.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2022, 33 : S1595 - S1595

← 1 2 3 4 5 →